J Drugs Dermatol. 2023 Jun 1;22(6):588-593. doi: 10.36849/JDD.7432.
Precision medicine utilizes an individual’s genomics to improve diagnosis, prognosis, and therapy. The joint American Academy of Dermatology and National Psoriasis Foundation 2019 guidelines recognized the need to identify biomarkers that can predict the optimal biologic agent for an individual patient. This paper examines the current state of precision medicine in dermatology and how its use can improve outcomes in psoriasis.
A search of PubMed/MEDLINE using the terms precision medicine, personalized medicine, biomarkers, genomics, and dermatology was performed to identify relevant publications. An expert consensus panel was then convened to assign levels of evidence to each article using strength of recommendation taxonomy and create consensus statements requiring a two-thirds supermajority for agreement utilizing a modified Delphi approach.
Thirteen articles met inclusion and exclusion criteria and were assigned levels of evidence. The panel created 10 consensus statements on how precision medicine can improve patient outcomes, all of which received a unanimous (6/6) vote.
Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.
精准医学利用个体的基因组学来改善诊断、预后和治疗效果。美国皮肤病学会和国家银屑病基金会于 2019 年联合发布的指南认识到，有必要确定能够预测个体患者最佳生物制剂的生物标志物。本文探讨了皮肤科精准医学的现状，以及其在银屑病中的应用如何改善治疗效果。
通过在 PubMed/MEDLINE 中使用精准医学、个性化医学、生物标志物、基因组学和皮肤病等术语进行检索，以确定相关文献。然后召集一个专家共识小组，使用推荐强度分类法对每篇文章进行证据水平评估，并利用改良 Delphi 方法创建需要三分之二多数票达成一致的共识声明。
有 13 篇文章符合纳入和排除标准，并被分配了证据水平。专家组就精准医学如何改善患者预后创建了 10 项共识声明，所有声明均获得一致（6/6）投票。
选择用于治疗银屑病的生物制剂通常取决于患者偏好、提供者偏好和试错方法。通过使用精准医学测试，如 Mind.Px，医生可以帮助患者识别其病理生理学特有的生物标志物，并通过有针对性和基于证据的方法选择最佳药物。Zakria D、Brownstone N、Armstrong AW 等人。将精准医学纳入医学皮肤科临床实践：专家共识小组。J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.
